Lecanemab in Early Alzheimer’s Disease

20224,813 citationsJournal Articlebronze Open Access

Authors

Christopher H. van Dyck · University Memory and Aging Center

Chad J. Swanson · Eisai (United States)

Paul Aisen · University Memory and Aging Center

Randall J. Bateman · University Hospital Heidelberg

Christopher Chen · University Hospital Heidelberg

Michelle Gee · University Hospital Heidelberg

Michio Kanekiyo

Abstract

Lecanemab reduced markers of amyloid in early Alzheimer's disease and resulted in moderately less decline on measures of cognition and function than placebo at 18 months but was associated with adverse events. Longer trials are warranted to determine the efficacy and safety of lecanemab in early Alzheimer's disease. (Funded by Eisai and Biogen; Clarity AD ClinicalTrials.gov number, NCT03887455.).

Topics & Keywords

Alzheimer's disease research and treatments Neuroinflammation and Neurodegeneration Mechanisms Cholinesterase and Neurodegenerative Diseases

Publication Details

Published in: New England Journal of Medicine

Volume 388, Issue 1, pp. 9-21

DOI: 10.1056/nejmoa2212948

Field-Weighted Citation Impact: 530.70

Command Palette

Lecanemab in Early Alzheimer’s Disease

Authors

Abstract

Topics & Keywords

Publication Details